A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Research Service,VA Western New York Healthcare System, 2Department of Ophthalmology, (Ross Eye Institute), Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 3Pharmacology/Toxicology, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 4Physiology/Biophysics, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 5Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 6The RNA Institute,University at Buffalo- SUNY, 7The SUNY Eye Institute
Chapters
- 00:04Title
- 00:45Subretinal Injection
- 02:37Injection Site and Subretinal Bleb Mapping
- 04:03High Resolution Spectral-Domain Optical Coherence Tomography (HR-SD-OCT) Outer Retinal Degeneration Evaluation
- 07:47Results: Representative Outer Retinal Change Quantification and Post-Subretinal Injection 3D Mapping
- 08:54Conclusion
Aquí nos muestran un nuevo enfoque al uso de tomografía de coherencia óptica de dominio espectral de alta resolución (HR-SD-OCT) para facilitar la presentación de los agentes de terapia génica en el espacio subretinal, evaluar su cobertura areal y caracterizan la vitalidad del fotorreceptor.
Tags
Ultrahigh ResolutionMouseOptical Coherence TomographyIntraocular InjectionRetinal Gene TherapySubretinal InjectionVector DeliveryTherapeutic Agent ToxicityMinimally InvasiveReproducibleReal-time ObservationRetinal ImagingProptosisScleral DepressionRetinal Pigment EpitheliumSubretinal SpaceInjection OutcomesOCT Imaging
